Martin Gosling, PhD profile page

Professor Martin Gosling has spent his research career progressing the therapeutic potential of ion channels in both industrial and academic settings. Prior to co-founding Enterprise Therapeutics, Gosling was executive director in the Respiratory Disease Area of the Novartis Institutes for BioMedical Reseach, UK. Whilst with Novartis, he established an internal ion channel platform, was a successful project team leader for multiple drug discovery programs and played a lead role in defining the Novartis cystic fibrosis portfolio. Gosling holds a BSc and PhD in pharmacology from the Universities of Leeds and Aston, respectively. In addition to his position as chief scientific officer of Enterprise Therapeutics, he also holds the position of professor of molecular pharmacology at the University of Sussex.